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Objective: To investigate the effects of sodium channel–blocking antiepileptic
drugs (AEDs) on functional magnetic resonance imaging (fMRI) language net-
work activations in patients with focal epilepsy.
Methods: In a retrospective study, we identified patients who were treated at the time
of language fMRI scanning with either carbamazepine (CBZ; n = 42) or lamotrigine
(LTG; n = 42), but not another sodium channel–blockingAED.We propensity-matched
42 patients taking levetiracetam (LEV) as “patient-controls” and included further 42 age-
and gender-matched healthy controls. After controlling for age, age at onset of epilepsy,
gender, and antiepileptic comedications, we compared verbal fluency fMRI activations
between groups and out-of-scanner psychometric measures of verbal fluency.
Results: Patients on CBZ performed less well on a verbal fluency tests than those
taking LTG or LEV. Compared to either LEV-treated patients or controls, patients
taking CBZ showed decreased activations in left inferior frontal gyrus and patients
on LTG showed abnormal deactivations in frontal and parietal default mode areas.
All patient groups showed fewer activations in the putamen bilaterally compared
to controls. In a post hoc analysis, out-of-scanner fluency scores correlated posi-
tively with left putamen activation.
Significance: Our study provides evidence of AED effects on the functional neu-
roanatomy of language, which might explain subtle language deficits in patients
taking otherwise well-tolerated sodium channel–blocking agents. Patients on CBZ
showed dysfunctional frontal activation and more pronounced impairment of per-
formance than patients taking LTG, which was associated only with failure to
deactivate task-negative networks. As previously shown for working memory,
LEV treatment did not affect functional language networks.
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1 | INTRODUCTION
Lamotrigine (LTG) and carbamazepine (CBZ) are both
effective antiepileptic drugs (AEDs) and well-tolerated in
epilepsy patients.1 Cognitive deficits commonly associated
with AED therapy are rarely observed in patients receiving
LTG therapy, whereas CBZ produces modest negative
untoward effects.1,2 Direct comparison of the 2 AEDs
revealed significantly better cognitive performance on LTG
than CBZ.1 It remains unclear how these 2 widely used
antiepileptic drugs specifically affect cognition in patients
with epilepsy.
In cognitive functional magnetic resonance imaging
(fMRI), consistent and reproducible patterns of activation
and deactivation are elicited by goal-directed tasks, includ-
ing language and memory. The default mode network
(DMN) represents a set of brain regions that is commonly
deactivated during goal-directed tasks and has been tradi-
tionally associated with mind-wandering and envisioning
the future.3,4 The verbal fluency fMRI task usually elicits
the activation of frontal lobe areas, particularly the domi-
nant inferior frontal gyrus (IFG), middle frontal gyrus
(MFG), anterior cingulate, and precentral cortices, as well
as the insular, superior temporal, and parietal cortices and
the cerebellum.5–7 Its relatively low demand makes it an
important tool for the assessment and lateralization of lan-
guage function for presurgical evaluation.7,8
Pharmaco-fMRI is a promising emerging application to
probe pharmacological effects on functional neuroanatomy,
and can help to determine early treatment response, mecha-
nisms of drug efficacy, and side effects.9–11 Our recent
studies showed that both valproate (VPA) and levetirac-
etam (LEV) may lead to a normalization of the altered
fMRI activation patterns in genetic generalized1,12and focal
epilepsies,1,2,13 respectively. Previous cognitive fMRI stud-
ies probing the effects of topiramate (TPM),1,14–19 which is
often associated with cognitive impairment and improve-
ment of psychometric measures after dose reduction or dis-
continuation,3,4,20–22 and zonisamide (ZNS), which has
similar but less pronounced cognitive side effects,5–7,22,23
highlighted the following patterns of dysfunctional fMRI
activations: (1) decreased activation in task-positive
regions, that is, dominant inferior and middle frontal gyri
(IFG and MFG); and (2) failure to deactivate task-negative
regions, including the DMN.7,8,19 TPM was particularly
related to impaired attenuation of language-associated deac-
tivation.9–11,19
Relatively few studies24,25 have investigated the fMRI
correlates of CBZ and LTG in patients with epilepsy. The
aim of this retrospective study was to assess how LTG and
CBZ influence task-related fMRI activation or deactivation
patterns, and to improve our understanding of medication-
specific effects on cognitive functional anatomy. To control
for the effects of comedication and disease-related factors,
we used LEV-treated patients as a “patient control” group,
owing to its normalizing effects on cognitive fMRI para-
digms; patients on LEV showed similar task-related deacti-
vation patterns to healthy controls.13 We used healthy
control subjects (CTR) to detect common cognitive effects
of different AEDs. We hypothesized that impaired verbal
fluency performance is associated with failure either to
activate task-positive or to deactivate task-negative regions
as assessed by a language fMRI paradigm.
2 | MATERIALS AND METHODS
2.1 | Participants
From our clinical verbal fluency fMRI database, we
selected patients with drug-refractory epilepsy who had
undergone clinical language fMRI scans at the Chalfont
Centre for Epilepsy (UK) between March 2010 and March
2017 as part of their presurgical evaluation. All patients
were adults and had been seen at the adult epilepsy clinics
of the National Hospital for Neurology and Neurosurgery
and Chalfont Centre for Epilepsy. We included patients
who were taking 1 of the following 3 AEDs: CBZ, LTG,
or LEV, either alone or in combination with other AEDs,
but not with other sodium channel blockers (lacosamide
and/or oxcarbazepine), TPM, or ZNS.19 We also excluded
patients who were receiving treatment with psychotropic
medications, such as antidepressant and antipsychotic
agents.
All patients had to be fluent in English and able to
understand the task instructions for testability with the lan-
guage fMRI task. We could not control for task compli-
ance, because our standard clinical verbal fMRI paradigm
Key Points
• A verbal fluency functional MRI approach was
employed to investigate the effects of carba-
mazepine and lamotrigine on cognition
• Those on carbamazepine showed less activation
in left inferior frontal gyrus compared to those
taking levetiracetam or healthy controls
• Those on lamotrigine had more failed task-
related deactivations compared with those on
levetiracetam or healthy controls
• Patients on carbamazepine showed dysfunctional
frontal activation and more pronounced impair-
ment of performance than those on lamotrigine
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is conducted covertly. Hence, we excluded all patients
without activations of language-relevant regions (IFG and
MFG) from the analysis. Also, we excluded patients with
data acquired postoperatively and those with large lesions
or tumors (>2 cm) to avoid problems with imaging normal-
ization and further statistical analysis.
Seventy-four patients on LEV, 68 on LTG, and 51 on
CBZ were eligible. Starting with the LEV and LTG groups,
we propensity-matched (PSM) CBZ patients for the vari-
ables of age at scan, age at onset, sex, language laterality
index (LI), total number of medications, localization, and
localization laterality, using SPSS version 22.0 (IBM,
Armonk, NY, USA). We included 42 patients in each AED
group in the final analysis. We further matched 42 English-
speaking CTR, recruited from the local community, using
the variables age, gender, and language laterality index in
the PSM analysis for 3 AED groups.
2.2 | MRI data acquisition and fMRI
paradigm
Gradient echo-planar images providing blood oxygen
level–dependent (BOLD) contrast were acquired on a 3-T
Excite HDx scanner (General Electric, Milwaukee, WI,
USA), using a standard 8-channel receive coil. Each vol-
ume comprised 50 contiguous oblique axial slices, ensuring
full brain coverage, with 2.5-mm slice thickness, 64 9 64
matrix, and 24-cm field of view, providing an in-plane
voxel size of 3.75 9 3.75 mm. Echo time was 25 millisec-
onds, and repetition time was 2.5 seconds. A scanner
upgrade had taken place in 2013, but the scanning protocol
remained the same. Patients performed a covert verbal flu-
ency task lasting for 5 minutes. During the paradigm, 30-
second blocks of task were alternated with 30-second
blocks of crosshair fixation as a control condition. Patients
were instructed to covertly generate words starting with a
visually presented letter (A, D, E, S, W).
2.3 | MRI data analysis
fMRI data were preprocessed with Statistical Parametric
Mapping 8 (SPM8) toolkit, version 6313 (http://www.fil.
ion.ucl.ac.uk/spm/), which included realignment, spatial
normalization to the Montreal Neurological Institute (MNI)
template supplied by SPM8, resampling (isotropic
3 9 3 9 3 voxels), and spatially smoothing (8 mm). We
performed the statistical fMRI analyses at the first level
(single subject), and then at the group level. At the subject
level, the task was modeled by convolving the vector of
block onsets with a canonical hemodynamic response func-
tion to create regressors of interest, and motion parameters
were included as confounds. Contrast images for each par-
ticipant were created for task-relevant activation and
deactivation. For the second-level analysis, we introduced
CTR and entered activation contrasts for each patient and
control into a full factorial design with group as a factor
(CBZ, LEV, LTG, CTR) and age, gender, and LI as regres-
sors. All disease-related variables used in the PSM analysis
were entered as regressors of no interest for patient-to-
patient group comparison (CBZ, LEV, and LTG). An
exploratory statistical threshold was set at P < .005 uncor-
rected with a 10-voxel minimum cluster size extent thresh-
old.1,26 To be able to examine whether group differences
were related to activation or deactivation, we masked the
results with a binarized average task activation map of the
controls and then with the binarized deactivation map to
include the contrast-relevant brain areas.
Interpretation of the results at the subject level and
group level was not blinded, because resultant maps repre-
sent t maps at a predefined statistical threshold. We
anatomically objectified peak activations from group com-
parisons with coordinates in the MNI template.
2.4 | Language Lateralization Index
Laterality indices (LIs) of statistic parametric maps were
measured to quantitatively assess hemispheric dominance
for language.27 For each subject, we used the bootstrap
method of the lateralization index toolbox in SPM828 on
verbal fluency statistic parametric maps. In accord with
previous studies,29,30 activated voxels in IFG and MFG for
the verbal fluency paradigm were computed according to
the formula LI = (L  R)/(L + R), where L = left and R =
right. A positive LI indicates left hemispheric dominance
and a negative index indicates right hemispheric lateraliza-
tion. LIs were subsequently classified as left-hemisphere
dominant (LI > +0.2); atypically dominant, comprising a
bilateral distribution (0.2 ≤ LI ≤ +0.2); and right-hemi-
sphere dominant (LI < 0.2).29,31 We matched the groups
for language LIs to control for differences in hemispheric
language dominance.
2.5 | Neuropsychological measures,
correlation with language networks, and dose
dependence of the patterns of activation and
deactivation
Out-of-scanner neuropsychological results are available in
some participants (Table 1). This mainly included tests
measuring language function: verbal and category fluency
tests, National Adult Reading Test to provide an estimate
of general intellectual level (intelligence quotient [IQ]), and
McKenna Graded Naming Test of expressive language
functions. In these participants, post hoc analyses were
conducted correlating these scores with the task-activation
patterns. Dose dependence was conducted correlating the
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dose of each patient of different AED group with task-acti-
vation/deactivation patterns. Positive and negative correla-
tions were explored using these parameters as regressors in
1-sample t tests over the whole brain for each language
task.13,32 The level for significance was P < .005 uncor-
rected with a 20-voxel threshold extent.
2.6 | Statistical analysis of clinical,
demographic, and cognitive measures
Statistical analysis of clinical and behavioral data was con-
ducted with SPSS 22.0. For normally distributed data, we
used 1-way analysis of variance and 2-sample t test for
post hoc analysis with a significance threshold of 0.05
(Bonferroni-corrected). We applied v2 tests to categorical
data, and the Kruskal-Wallis or Mann-Whitney U test to all
other measures with a statistical significance threshold of
.05 (Bonferroni-corrected).
2.7 | Standard protocol approvals,
registrations, and patient consent
This study was approved by the Joint Ethics Committee of
the National Hospital for Neurology and Neurosurgery and
University College London Institute of Neurology. The
Research Ethics Committee classified this work as evalua-
tion of clinical services (routine language fMRI), and there-
fore individual consent from patients was not needed.
3 | RESULTS
Table 1 provides further demographic and clinical details
of subjects. Appendix S1 presents the details of AEDs for
each patient in this study.
3.1 | Cognitive performance
There were significant group differences in cognitive test
performance for verbal and category fluency tests (Table 2).
Post hoc group comparisons revealed that all 3 AED
groups performed worse in letter fluency than CTR (CBZ,
P < .001; LEV, P = .002; LTG, P = .029). For category
fluency, this was demonstrated for the CBZ group
(P < .001). There was no statistical difference between
LEV- and LTG-treated patients, either in letter (P = .299)
or category (P = .525) fluency, and both LEV and LTG
groups performed better than patients on CBZ for both flu-
ency measures (letter fluency: LEV vs CBZ, P = .015;
LTG vs CBZ, P = .004; category fluency: LEV vs CBZ,
P = .05; LTG vs CBZ, P = .012).
3.2 | Language Lateralization Index
Five LTG-treated, 5 CBZ-treated, and 2 LEV-treated
patients as well as 4 CTR exhibited right-hemisphere lan-
guage dominance, whereas 1 LTG-treated, 2 CBZ-treated,
and 3 LEV-treated patients had bilateral language
TABLE 1 Demographic and neuropsychological measures
Demographic and clinical details On LEV, n = 42 On LTG, n = 42 On CBZ, n = 42 CTR, n = 42 P
Age, y, median (range) 36.5 (18-66) 34.5 (16-72) 37.5 (23-69) 35.5 (21-64) .713
Gender, F/M 25/17 21/21 19/23 21/21 .613
Handedness, R/L/A 33/8/1 37/5/0 37/5/0 38/4/0 .596
Laterality index, median (range) 0.76 (0.66 to 0.98) 0.74 (0.83 to 1) 0.62 (0.85 to 0.99) 0.80 (0.66 to 1) .394
Age at onset, y, median (range) 16.8 (1-49) 15.0 (1-49) 14.3 (1-40) .319
Duration, y, median (range) 19.0 (3-51) 18.0 (4-28) 20.5 (4-62) .207
Pathology, temporal/frontal/parietal/unknown 32/8/1/1 32/10/0/0 31/10/1/0 .735
Pathology lateralization, L/R/bilateral/unknown 22/13/6/1 21/12/6/3 15/18/9/0 .296
Scanner, original/upgraded 26/16 22/20 25/17 .655
AEDs, median (range) 2 (1-4) 2 (1-4) 2 (1-3) .411
Mono-/polytherapy, n 13/29 13/29 13/29 1
Monotherapy 13 13 13 .609
2 AEDs 16 16 22
3 AEDs 12 8 7
4 AEDs 1 2 0
Dose, mg, median (range) 2000 (375-4000) 300 (50-800) 1000 (200-1600)
Pearson v2 was used for dichotomous variables, and Kruskal-Wallis test was used for all other variables (P < .05).
A, ambidextrous; AED, antiepileptic drug; CBZ, carbamazepine; CTR, healthy control subjects; F, female; L, left; LEV, levetiracetam; LTG, lamotrigine; M, male;
R, right.
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representations. Mann-Whitney U test for independent sam-
ples did not indicate a significant difference in distribution
of LIs across the 3 groups (U = 877.5, P = .96). There
was no correlation of lateralization indices with age at
onset, disease duration, or number of comedications
(P > .05).
3.3 | fMRI results
One-sample t tests of task-relevant activations and deactiva-
tions of each group are demonstrated in Figure 1. Areas of
significant activations were observed in frontal language
areas, including the IFG, MFG, bilateral supplementary
motor areas (SMAs), and left lateral parietal region. Deacti-
vated areas of the DMN included bilateral precuneus, pos-
terior cingulate, angular gyrus, and medial prefrontal and
lateral temporal cortices.
3.4 | Comparison of TPM, ZNS, and LEV
groups
Compared to patients taking LEV, CBZ-treated patients
showed less activation of left IFG (Figure 2A; Table 3).
LTG-treated patients exhibited fewer task-related deactiva-
tions in bilateral frontal and parietal regions, as well as in
the right middle temporal gyrus (Figure 2A; Table 3).
3.5 | Comparison of patient groups with
CTR
Compared with CTR, all 3 AED groups showed less acti-
vation of the bilateral putamen. Available out-of-scanner
verbal and category fluency scores positively correlated
with activation in left putamen in all participants (patients
and controls): the higher the scores, the higher the activa-
tion in left putamen (Figure 2C). In addition, CBZ-treated
patients showed reduced activation in left IFG, left middle
temporal lobe, left inferior parietal lobe, left SMA, and
right middle temporal lobe, which are mainly in task-posi-
tive network regions (Figure 2, Table 3); LTG-treated
patients showed impaired deactivation in temporal and
frontal areas bilaterally and in left parietal lobes, which are
mainly task-negative networks, and less activation in left
SMA (Figure 2, Table 3). All control scans were performed
prior to the scanner upgrade in 2013. Patients scanned prior
to the upgrade were matched to controls for each AED
group (CBZ, n = 25; LTG, n = 22; LEV, n = 25), and the
group differences were similar to those above. In each
AED group, the patterns of activation and deactivation did
not correlate with dosage accordingly (P > .05).
4 | DISCUSSION
We investigated language paradigm-specific fMRI effects
of 2 commonly used AEDs in focal epilepsy; CBZ-treated
patients activate less the left IFG, whereas LTG-treated
patients fail to deactivate task-related areas compared with
either patients receiving LEV or CTR.
Patients on CBZ showed dysfunctional network activa-
tion in the left IFG, which was not observed in patients on
LTG, and which relates to poorer out-of-scanner perfor-
mance on fluency tasks in accordance with previous cogni-
tive findings.1,2 The first pharmaco-fMRI study in temporal
lobe epilepsy24 reported reduced fMRI activation within
the medial temporal lobe during a memory task, which cor-
related with CBZ serum levels: the higher the CBZ levels,
the lower the fMRI activation. In a recent study on brain
connectivity,25 CBZ treatment had a region-specific effect
on the limbic circuit and thalamus network. In our previous
pharmaco-fMRI studies,19 we observed impaired task-
related fMRI activation, including Broca’s region as well
as dorsolateral frontal and parietal cortices activation, and
poorer performance on verbal fluency in patients on TPM
TABLE 2 Cognitive measures
Measure LEV LTG CBZ CTR P
































For letter and category fluency, analysis of variance was used to detect differences between groups at P < .05.CBZ, carbamazepine; CTR, healthy control subjects;
LEV, levetiracetam; LTG, lamotrigine; SD, standard deviation.
aPost hoc group comparisons (2-tailed t test, P < .05) revealed that both LEV and LTG groups performed better on letter and category fluency than the CBZ group,
and all 3 patient groups performed worse than healthy controls. For McKenna Graded Naming Test and National Adult Reading Test, healthy control data were not
available. Nonparametric testing (Kruskal-Wallis test) did not show any differences between the 3 different patient groups.
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and ZNS. Dorsolateral frontal and parietal cortices, acti-
vated by the verbal fluency task, are also part of extended
functional networks implicated in working memory and
attention.33 TPM and ZNS have frequently been linked
with higher-level cognitive dysfunction, whereas CBZ
seems to cause relatively less apparent cognitive impair-
ments. In this study, unlike TPM and ZNS, decreased acti-
vation in CBZ-treated patients was confined to the left
IFG.
Similar to patients on TPM,19 we show that LTG-trea-
ted patients failed to deactivate parts of the frontal and
parietal cortices including medial frontal gyrus and cuneus
and precuneus, which are nodes of the DMN.4 This
matches with previous results demonstrating that successful
task execution has been associated with effective deactiva-
tion of task-negative areas.4,34 In our recent study,19 TPM-
treated patients failed to deactivate task-relevant DMN
nodes compared to patients taking ZNS or LEV, which
was associated with more cognitive impairment than those
on ZNS. Moreover, direct comparison to ZNS shows that
TPM led to a failure to deactivate DMN nodes of language
task on the right hemisphere. ZNS treatment leads to simi-
lar but less pronounced impairment than TPM in epilepsy
patients.22,23 Our LTG-treated patients had similar out-of-
scanner verbal fluency performance to LEV-treated
patients, and both LTG- and LEV-treated patients per-
formed better than patients on CBZ. We suggest that the
failure to deactivate task-relevant DMN nodes might also
affect language performance, but to a lesser degree than
reduced activation in Broca’s area.
Interestingly, we found an effect of all AEDs on activa-
tions in the putamen bilaterally, when compared with con-
trols. The greater the activation of the left putamen, the
better were out-of-scanner letter and category fluency
scores. These findings in patients are in line with a sus-
pected role of the left putamen in speech production and
processing,35 and may account for the negative effect all
AEDs have on cognitive processing. At the same time, sub-
cortical structures, like the putamen, also play important
roles in ictogenesis,36 which might reflect a common site
for the antiseizure effects of AEDs. With the present study
design, it is difficult to ascribe these effects to the effect of
AEDs or the influence of seizure activity. Future prospec-
tive longitudinal studies with well-controlled seizure char-
acteristics in AED monotherapy will help further address
the underlying mechanisms.
FIGURE 1 One-sample t tests of functional magnetic resonance imaging activation and deactivation maps for the 3 different patient groups
on carbamazepine (CBZ), levetiracetam (LEV), and lamotrigine (LTG) and healthy controls (CTR) are demonstrated on a surface-rendered brain
template. Task-relevant regions (red) include bilateral inferior and middle frontal gyrus (left > right), bilateral supplementary motor area, the left
dorsolateral parietal region, and bilateral inferior occipital lobes. Areas of task-related deactivations (blue) include the bilateral precuneus,
posterior cingulate, angular gyrus, and medial prefrontal and lateral temporal cortex. P < .005, 20-voxel threshold extent. L, left; R, right
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We included LEV-treated patients as a “patient control
group.” Our recent fMRI studies13,19 showed a “normaliz-
ing” effect of LEV on cognitive networks without necessar-
ily improving cognition. Task- and syndrome-specific
regional fMRI effects as well as dose dependency were
demonstrated with a verbal and visual-spatial working
memory task. Patients on LEV displayed an augmentation
of task-related deactivation in the affected temporal lobe
compared to patients without LEV. In the present study,
we also did not detect abnormal deactivation patterns in
LEV patients, replicating previous findings of normaliza-
tion of deactivation patterns on LEV,13,19 which justifies
our inclusion of LEV-treated patients as a patient control
group. We argue that “normalization, or more pronounced
deactivation patterns” may represent a beneficial drug
effect, as data in healthy subjects and epilepsy patients
show that progressive deactivation of the DMN nodes dur-
ing cognitive tasks is associated with improved perfor-
mance.37
The strengths of this study include the large sample size,
well-matched disease characteristics, and introduction of
healthy controls as a comparison group. Our study is still
limited by its retrospective nature. The statistical threshold
(P < .005 with 10-voxel threshold extent) used for the sec-
ond-level analysis was uncorrected but enables an explora-
tory view of the differences between AED treatment groups,
with peak activations within implicated regions almost all
reaching P < .001 uncorrected (Table 3). We precisely
matched participants to reduce factors that would impact
results, but still the majority of patients were receiving multi-
ple AEDs (mainly 2 compounds; 2 were on 4 AEDs). This
may have contributed to poor cognitive performance and
may represent an additional source of variance. In addition,
AED plasma concentrations were not examined at the time
of the scan. Recent research has shown that every additional
AED leads to further cognitive impairment.38 We tried to
control for the effect of comedication as much as possible,
by excluding medications that are known to affect the
FIGURE 2 Significant group differences between patients on carbamazepine (CBZ), levetiracetam (LEV), and lamotrigine (LTG) and
healthy controls (CTR) are demonstrated on a surface-rendered brain template, and the subcortical changes are demonstrated on a coronal brain
template with a bar chart indicating z score. A, Patients on CBZ activated less in the left inferior frontal gyrus than patients on LEV. In patients
on LTG, deactivation was reduced in the task-negative areas, including the middle frontal gyri and left dorsal parietal region of the precuneus,
compared with patients on LEV and CBZ. P < .005, 10-voxel threshold. B, All 3 groups of patients activated the putamen less bilaterally
(left > right) than CTR. Patients on CBZ activated the left inferior frontal gyrus less than CTR. There was less deactivation in the bilateral
medial frontal gyri and bilateral lateral temporal regions, left rolandic operculum, and left inferior parietal lobule in patients on LTG. P < .005,
10-voxel threshold. C, The clinical neuropsychological performance on letter fluency (143) and category fluency (145) in 4 groups together
positively correlates with activation in the left putamen. P < .005, 20-voxel threshold. L, left; R, right
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activation patterns, such as TPM and ZNS19 and other
sodium-channel blockers (oxcarbazepine and lacosamide). In
addition, we propensity-matched groups for the number of
AEDs, and as an additional measure, individual AED
comedication was included as a regressor of no interest in
the fMRI analysis model, a standard methodology in fMRI
analysis. Out-of-scanner cognitive data were not available in
all patients. All patients had tried multiple AED treatments
but still suffered from refractory epilepsy. The effect of sei-
zures on our findings, however, could not be quantified in
terms of frequency or severity.
Identifying language lateralization with fMRI is crucial
for risk assessment during presurgical evaluation.8 It would
thus be important to establish whether fMRI changes due to
AEDs can lead to altered lateralization of language. As
groups were matched for LIs, we cannot comment on the
potential effects of CBZ and LTG on language lateralization.
Although the number of AEDs taken by an individual was
not correlated with LIs, the specific effects of single AEDs
would be more appropriately investigated by longitudinal
studies carried out before and after treatment initiation.
Together with our previous findings,13,19 patients on
CBZ and ZNS showed similar dysfunction within task-
related activation networks, which was associated with
poorer performance in verbal fluency. Patients on LTG only
presented with abnormal deactivation, associated with lim-
ited impact on language function. Patients on TPM showed
both decreased task-relevant frontal activation and abnormal
deactivation of task-negative networks, which was associ-
ated with the most pronounced impairment of language and
TABLE 3 Anatomic description and peak activations of resultant






Patients on LEV > patients on CBZ
Left inferior frontal
gyrus
60, 11, 7 3.37 <.001
Patients on LEV < patients on LTG
Left cuneus 6, 76, 25 3.43 <.001
Left medial frontal
gyrus
6, 50, 13 3.39 <.001
Left precuneus 9, 55, 31 3.14 .001
Left angular
gyrus
45, 67, 31 2.81 .003
Right hippocampus 27, 13, 17 2.89 .002
Right middle temporal
lobe
48, 4, 20 2.87 .002
Right calcarine 15, 58, 7 2.68 .004
Patients on LEV > patients on LTG
Left precentral gyrus 57, 13, 49 3.35 <.001
Patients on CBZ < patients on LTG
Left inferior parietal
lobe
39, 37, 37 3.26 .001
Left cuneus 0, 88, 48 3.17 .001
Left calcarine 12, 73, 7 2.8 .003
Right anterior cingulate
cortex
9, 20, 22 2.85 .002
Healthy controls > patients on CBZ
Left putamen 18, 11, 2 4.5 <.001a
Left inferior frontal
gyrus
51, 14, 19 4.14 <.001
Left supplementary
motor area
3, 20, 46 3.53 <.001
Left middle temporal
lobe
63, 25, 5 3.14 .001
Left thalamus 9, 16, 4 3.28 .001
Left inferior parietal
lobe
51, 37, 46 2.95 .002
Right putamen 21, 20, 2 3.65 <.001
Right middle temporal
lobe
60, 25, 8 3.2 .001
Healthy controls > patients on LEV
Left putamen 21, 8, 4 4.13 <.001
Right putamen 24, 10, 14 3.73 <.001
Right middle temporal
lobe
60, 22, 8 3.36 <.001
Right middle frontal
gyrus








Healthy controls > patients on LTG
Left putamen 21, 8, 2 3.98 <.001
Left supplementary
motor area
3, 2, 67 3.37 <.001
Right putamen 24, 5, 1 3.06 .001
Healthy controls < patients on LTG
Left precuneus 15, 55, 40 3.68 <.001
Left rolandic operculum 39, 19, 22 3.41 <.001
Left fusiform 30, 49, 8 3.18 .001
Right medial frontal
gyrus
3, 62, 8 3.45 <.001
Right calcarine 12, 61, 13 3 .001
Coordinates are given in MNI space.
CBZ, carbamazepine; LEV, levetiracetam; LTG, lamotrigine; MNI, Montreal
Neurological Institute.
aLeft putamen activations are shown corrected for multiple corrections in
healthy controls versus patients on CBZ, familywise error, P < .05.
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working memory.19,23 In contrast, both VPA and LEV
appear to restore the fMRI activation patterns in genetic
generalized12 and focal epilepsies,13 respectively. These
fMRI verbal fluency activation and deactivation patterns are
not dose-dependent. In our previous study,13 dose depen-
dence was specific to memory in LEV patients and was
more apparent in a more demanding nonverbal task than in
a verbal memory task. Hence, it suggests that dose depen-
dence may not be obvious in a relatively “pure” verbal
fMRI task. Although our observed results are only robust
with high sensitivity in group comparisons, they could pro-
vide valuable information for interpreting clinical language
fMRI scans in a variety of patients. There were no differ-
ences in the National Adult Reading Test, which is consid-
ered to reflect comorbid IQ. Thus, it is unlikely that our
results are due to an uncontrolled sample bias with patients
with lower cognitive abilities choosing the older AED. The
observed BOLD changes provide testable hypotheses for
intrasubject initiation and withdrawal studies of AEDs, as
shown previously for TPM.16 Prospective, longitudinal
studies with cognitive fMRI and neuropsychological data
collection before and after the initiation or withdrawal of
these AEDs may be instrumental to better characterize
AED-specific effects and disentangle the effects of different
AEDs on epileptic and functional language networks.
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